Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
04 9월 2024 - 1:30AM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to announce that leading independent proxy
advisory firm Institutional Shareholder Services Inc. (“ISS”) has
recommended Shareholders vote “FOR” all the proposed resolutions at
the upcoming Annual and Special Meeting of Shareholders (the
“Meeting”) to be held on September 12, 2024.
Leading independent third party proxy advisory
firm ISS has recommended that shareholders vote
FOR all the proposed resolutions.
The Board of Directors of XORTX
recommends that Shareholders vote FOR ALL
proposed items
Your vote is important no matter how
many shares you hold. Please vote today.
The proxy voting deadline is 10:00 am
(Calgary time) on Tuesday, September 10, 2024
Meeting Details
XORTX will hold its meeting on September 12,
2024, at 10:00 am (Calgary Time) at the offices of the Company at
3710 – 33rd Street NW, Calgary.
Please visit the
Company’s website complete details and links to all relevant
documents ahead of the Meeting at the link below:
https://www.xortx.com/investors/news-events/ir-calendar/detail/7671/annual-and-special-meeting-of-shareholders.
Questions & Voting
If you have questions about the meeting matters or require
voting assistance please contact XORTX‘s proxy solicitation agent,
Laurel Hill Advisory Group at:
North American Toll Free: 1-877-452-7184 (1-416-304-0211 outside
North America)Email: assistance@laurelhill.com
About XORTX Therapeutics
Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more
information, please contact: |
|
|
|
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
Kim Golodetz, LHA Investor Relations |
|
kgolodetz@lhai.com or +1 212 838 3777 |
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied
forward-looking statements pursuant to applicable securities laws.
These forward-looking statements include, but are not limited to,
the Company's beliefs, plans, goals, objectives, expectations,
assumptions, estimates, intentions, future performance, other
statements that are not historical facts and statements identified
by words such as "expects", "anticipates", "intends", "plans",
"believes", "seeks", "estimates" or words of similar meaning. These
forward-looking statements and their implications are based on the
current expectations of the management of XORTX only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Such risks, uncertainties, and other
factors include, but are not limited to, our ability to obtain
additional financing; the accuracy of our estimates regarding
expenses, future revenues and capital requirements; the success and
timing of our preclinical studies and clinical trials; the
performance of third-party manufacturers and contract research
organizations; our plans to develop and commercialize our product
candidates; our plans to advance research in other kidney disease
applications; and, our ability to obtain and maintain intellectual
property protection for our product candidates. Except as otherwise
required by applicable law and stock exchange rules, XORTX
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained under the heading “Risk Factors” in
XORTX’s Annual Report on Form 20-F filed with the SEC, which is
available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024